practical oncology mast cell tumor wendy blount, dvm

64
Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Upload: naomi-rodgers

Post on 18-Dec-2015

232 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Practical OncologyMast Cell Tumor

Wendy Blount, DVM

Page 2: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Mast Cell Tumor

• Mast cell granules contain histamine and heparin, among other things

• Degranulation is largely responsible for symptoms

• Release of histamine– Increased gastrin secretion (anorexia, ulcers,

hematemesis)– Anaphylactoid reaction

• Release of heparin – less clinically significant

Page 3: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Mast Cell Tumor• Most often found on the skin– Most common skin tumor in the dog– Brachycephalics & retrievers predisposed

• 2nd most common cancer in dogs• Also visceral & elsewhere– Gastrointestinal, Spleen, bone marrow

• Less common sites– Oropharyngeal– Mediastinum– CNS– Nail bed, ocular & periocular

Page 4: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Mast Cell Tumor• Can have many different appearances• Can be infiltrated with fat• Symptoms can be waxing and waning• Tumor gets bigger and smaller over time• 5-15% have multiple masses at

presentation• 20-50% will have more MCT in the future,

even if the first are cured

Page 5: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Etiology• Allergic skin disease?• C-KIT mutation (aka SCFR, CD117)– In “high risk MCT” (high grade II & all grade III)– These have decreased survival time– can be treated with tyrosine kinase inhibitors

(Palladia & Kinavet-CA1 )– SCFR – stem cell factor receptor– C-KIT normally regulates proliferation,

migration and differentiation– When C-KIT is mutated, it is constantly turned

on, dysregulating cell growth an promoting malignancy

Page 6: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Clinical Signs• GI Signs– Anorexia, vomiting, melena

• Pruritus and skin flushing• Facial swelling• Weakness, lethargy• Delayed wound healing• Darier’s Sign– swollen, itchy, red skin after scratching or

stroking the skin

Page 7: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

• GI Signs– Anorexia, vomiting, melena

• Pruritus and skin flushing• Facial swelling• Weakness, lethargy• Delayed wound healing• Darier’s Sign– swollen, itchy, red skin after scratching or

stroking the skin

Clinical Signs

Page 8: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Staging for Metastasis

Eva GeromeBonham TX

Chris Longo – Diamondhead, MS

Melanie Enger, - Lufkin TX

Page 9: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Diagnosis• FNA Cytology often diagnostic– Round cells with or without granules– Granules intracellular or in background– Granules form a halo around the relatively

pale nucleus– eosinophils

• Give diphenhydramine before or right after aspiration– FNA can cause degranulation – Dexamethasone as well if mass is visibly

inflamed

Page 10: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Diagnosis• FNA Cytology often diagnostic– Round cells with or without granules– Granules intracellular or in background– eosinophils

• Give diphenhydramine before or right after aspiration– FNA can cause degranulation – Dexamethasone as well if mass is visibly

inflamed

Page 11: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Diagnosis• FNA Cytology often diagnostic– Round cells with or without granules– Granules intracellular or in background– eosinophils

• Give diphenhydramine before or right after aspiration– FNA can cause degranulation – Dexamethasone as well if mass is visibly

inflamed

Page 12: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Diagnosis• FNA Cytology often diagnostic– Round cells with or without granules– Granules intracellular or in background– eosinophils

• Give diphenhydramine before or right after aspiration– FNA can cause degranulation – Dexamethasone as well if mass is visibly

inflamed

Page 13: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Diagnosis• FNA Cytology often diagnostic– Round cells with or without granules– Granules intracellular or in background– eosinophils

• Give diphenhydramine before or right after aspiration– FNA can cause degranulation – Dexamethasone as well if mass is visibly

inflamed

Page 14: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Staging for Metastasis• Histopathology for grading– Excisional if resectable– Incisional if not

• FNA draining lymph node– Clusters of mast cells likely metastasis– Single mast cells likely not

• Abdominal US with FNA liver and spleen• CBC, panel, buffy coat

Page 15: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Staging for Metastasis• Non-resectable MCT

Page 16: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Staging for Metastasis• Non-resectable MCT

Page 17: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Staging for Metastasis• Non-resectable MCT

Page 18: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Staging for Metastasis• Lymph node cytologies

Page 19: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Staging for Metastasis• Lymph node cytologies

Page 20: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Staging for Metastasis• Lymph node cytologies

Page 21: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Tumor Stage (WHO)• Stage 0 – microscopic disease only• Stage I – tumor confined to the dermis• Stage II – tumor does not infiltrate

subcutaneous tissues, lymph node metastasis

• Stage III – large, infiltrating tumor or multiple tumors

• Stage IV – distant metastasisConsideration is being given to reducing

stage of multiple dermal tumors

Page 22: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Histopathology• grade• Mitotic Index (MI)• Surgical margins – clean, narrow or dirty• Invasiveness – dermal or invasive

(subcutaneous/muscle)

Histopathology tells a great deal about prognosis and treatment indicated

Page 23: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Histopathologic Grading• Grade I – well differentiated, behaves

benignly• Grade II – intermediate differentiation,

behavior is widely variable– Low grade II – often behaves benignly– High grade II – C-kit mutation, often behaves

malignantly– Determined by MSU prognostic panel (form)

• Grade III – anaplastic, aggressive behaviorThis is the Patnaik SystemObsolete system has grade I the worst and

grade III the best prognosis

Page 24: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Surgery• Mainstay of low grade MCT treatment• Mast Cell Tumors often extend well beyond

the visible mass• Diagnose by FNA before you excise• Lateral margins 2-3 cm beyond visible mass– Small tumors <1 cm, 1.5-2cm margins may be

adequate• One fascia layer deep to visible mass• Avoid manipulating the tumor• Intraoperative cytologies on 4 lateral and

deep margins can be helpful

Page 25: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

SurgeryPrednisone for pre-surgical cytoreduction• Out of favor by oncologists at this time• I still like use it– Stabilizes lysosomal membranes – may

prevent degranulation caused by surgery– Controls inflammation around the tumor so

tumor borders are easier to see– Usually makes the dog feel better, so client

perceives better toleration of surgery• Prednisone 40 mg/m2 PO SID x 7days, then

QOD

Page 26: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

SurgeryRe-excision where borders are dirty on

grade I or II• Grade III tumors considered systemic– More surgery only for local palliation

• 3 cm beyond original surgery• One fascia layer deeper than original

surgery• Complete resection results in long survival• If clean borders, 95% cured with second

excision, using these rules

Page 27: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

SurgeryNeoAdjuvant Therapy• Given to a patient with non-resectable

tumor in hopes of making it resectable• Chemotherapy and/or radiation• Best managed by medical and/or radiation

oncologists• Need to understand effects of neoadjuvant

therapy on healing and when and how to do surgery

Page 28: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Sandra Goodwin – Forney TXSandra Goodwin’s Compadre

Betsy Hoffman Robinson – League City TX

Page 29: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Chemotherapy• Not indicated for multiple dermal MCT

that are cured by excision• To deal with MCT at the tumor borders

when radiation not possible• To improve post-surgical prognosis for high

risk grade II and all grade III MCT• To palliate metastatic or systemic disease• Surprisingly, there are few studies to

evaluate efficacy of various protocols

Page 30: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyVinblastine and prednisone (VP)• Median survival 134 days (5 months) – gross disease

after surgery• Median survival 1013 days (3 years) – microscopic

disease after surgery• 45% survival at 2 years• Half of these had surgery prior to chemo• This has not been my experience with grade III

– Most dead in 2-4 months– All gone within the year

• Vinblastine 2-2.2 mg/m2 IV over 10 min once weekly for 4 weeks, then every other week for 4 doses

• Prednisone 40 mg/m2 PO SID x 2 weeks then QOD

Page 31: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyCCNU• 60-70 mg/m2 PO q3-4 weeks– 4 week interval the first time, then shorten if

symptoms return during the 4th week– Baseline liver tests (ALT, SAP, albumin)– Pretreat with diphenhydramine

• Check before 3rd dose and then prior to each• Stop if signs of liver disease to prevent liver

failure• 6-8 doses common maximum– I have reached 12 at most

• Grade III median survival 2 months

Page 32: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyAlternating VP and CCNU• Alternate vinblastine and CCNU every 2

weeks for a total of 8 treatments– Doses on previous slides

• Prednisone 2 mg/kg PO SID tapered gradually to maintenance dose of 0.5 mg/kg PO SID x 6 months

• Macroscopic disease grades II and III– 3 remission, 4 PR– median duration of response 58 days

• 2 patients did not reach 4th CCNU treatment due to ALT >1000

Page 33: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyVinblastine, prednisone, cyclophosphamide• Study on high risk MCT• Median progression free interval of more

than 2 years• Median survival 6 years• Grade III and those who needed reduction

of vinblastine dose did not do as well• New protocol, but this may become a

popular protocol in the future

Page 34: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Chemotherapy• Vincristine alone not effective for MCT• COP can work well for grade II MCT• Many dirty border grade II do very well

with most protocols– many months, years or cured

• Some grade II with dirty borders spontaneously resolve– Are malignant MCT indistinguishable from

inflammatory reaction?

Page 35: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Chemotherapy• Because of the VP study, most oncologists

prefer VP to CCNU or both for grade III• My experience is that outcome is similar

with all 3 protocols for grade III MCT– Palliative therapy often does just as well– A significant proportion do not respond at all

Page 36: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Chemotherapy

Page 37: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyPalladia and Kinavet-CA1/Masivet• Tyrosine kinase (TKI) inhibitors• Prednisone and TKI are the chemo drugs

with direct cytotoxicity for MCT– Probably the most effective chemo for high

grade MCT • Not appropriate for low grade MCT due to

toxicityA game changer for high grade very large

MCT

Page 38: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyPalladia and Kinavet-CA1/Masivet• 25% of grade II & III MCT have C-KIT

mutation• Blocking wild type or mutated KIT causes

apoptosis in MCT• antiproliferative through KIT blockade• antiangiogenic through other MOA

Page 39: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyPalladia and Kinavet-CA1/Masivet• Indications for use:– Dogs >11-15 lbs only (not cats)– Non-resectable MCT• Dirty borders after re-excision

– Multiple diffuse or coalescing high grade MCT– Concurrent conditions precluding surgery or

multiple sedations for radiation therapy– High grade MCT or C-KIT mutation– Indicated with or without metastasis – Post Chemo – VP x 4 weeks, then Palladia

Page 40: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyPalladia and Kinavet-CA1/Masivet• Though both are TKIs, there can be resistance

to one but not the other– If one fails, try the other– Stable disease is a victory with either

• Palladia has more broad spectrum activity, and is thought to be more likely to cause clinical response than Kinavet

• Kinavet response can take up to 2-3 weeks• Gleevec is a TKI used in people, but it is very

expensive ($100-150 per pill)– Palladia $6-800, Kinavet $500 /month - 70lb dog

Page 41: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyKinavet Administration• 12.5 mg/kg PO SID– Dose chart on package insert (Client Info)– Cannot be used in dogs weighing less than 15

pounds• Dose reduction in response to adverse

events– stop Kinavet for 1-2 weeks– Reduce dose to 9 mg/kg/day when resumed

• Weekly CBC/panel for the first 6 weeks– Then every 3 weeks x 2– Then every 6 weeks thereafter

Page 42: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyPalladia Administration• 3.25 mg/kg PO QOD (or MWF)– Dose chart on package insert– With or without food

• Dose reduction in response to adverse events– Stop Palladia for 1-2 weeks– 0.5 mg/kg reduction when reduced– Minimum dose 2.2 mg/kg PO QOD

• Weekly CBC/panel for the first 6 weeks– Then every 3 weeks x 2– Then every 6 weeks thereafter

Page 43: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyPalladia Administration• GI side effects common– Make sure owner knows to STOP drug if

anorexia, vomiting, diarrhea• Dispense Cerenia and metronidazole at

the first visit to have on hand• Administer H1 and H2 blockers

concurrently

Page 44: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyPalladia Study – Bergman & Clifford, 2009

• Dogs with progressive disease on the blinded phase could enter open-label phase at any time

Page 45: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyPalladia Study – Bergman & Clifford, 2009• Statistically significant improvement in

objective response rate

Page 46: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyPalladia Study – Bergman & Clifford, 2009• 57.2% did not respond• Among responders, median duration of

response was 12 weeks• Median time to non-response or death was

18 weeks• 82% of dogs with C-KIT mutation responded• 54% of dogs without mutation responded• There was a placebo response– Likely due to spontaneously resolving

degranulation• Clin Cancer Res 2009; 15:3856-3865.

Page 47: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyPalladia Side effects

Page 48: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyPalladia Side effects• Dec. albumin – 13% Palladia, 8% Placebo• Palladia given long term leads to

glomerular disease and renal failure

Page 49: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyKenneth Kimbrough – Longview TXStephen Garner – Nacogdoches TX

Page 50: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyKinavet-CA1

Page 51: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyKinavet-CA1

Page 52: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

ChemotherapyPalliative therapy• Prednisone 40 mg/m2/day– Wean gradually to 0.5 mg/m2/day

• Antihistamines daily• H2 blocker or proton pump blocker– Cimetidine, ranitidine, famotidine– Omeprazole, esomeprazole

• sucralfate if ulcerated – Hematemesis, melena

Page 53: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Radiation Therapy

• Non-resectable high grade MCT• Regional lymph node metastasis• Grade II Stage 0 MCT with dirty margins– Disease free interval is increased compared to

no treatment– Similar outcome to re-excision if it is possible

• No indication to irradiate grade II MCT with clean borders

Page 54: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Treatments Not Recommended

• Deionized water injections– At one time recommended for cytoreduction

prior to surgery– Subsequent studies have proven ineffective– Risk causing degranulation– Pain on injection

• intralesional Vetalog or DepoMedrol– Reserved for those dogs who have too many

dermal MCT to remove and no evidence of systemic disease

Page 55: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Prognosis• Stage and grade much more important than

with LSA– Grade I with clean borders are cured by surgery– Low grade II clean borders usually cured by

surgery– High grade II clean borders should probably

have adjunctive chemo or radiation– High grade II with dirty borders should

definitely have adjunctive chemo and/or radiation and may have poor prognosis

– Virtually all of grade III die of their disease, often within a few months

Page 56: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

PrognosisIndicators of poor prognosis• Dirty borders on re-excision • High grade, advanced stage, MI >5• Breed- Shar pei• Systemic signs due to degranulation• Size and growth rate• Location – perineum, scrotum, nail bed,

mucocutaneous, muzzle• C-kit deletion and other histopath

prognostic indicators (MSU/AMC panels)

Page 57: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

PrognosisIndicators of better prognosis• Clean borders on excision• Low grade, low stage, MI <5• Breed – Boxers and Pugs

Page 58: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

PrognosisIndicators of better prognosis• Clean borders on excision• Low grade, low stage, MI <5• Breed – Boxers and Pugs

Page 59: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

PrognosisIndicators of better prognosis• Clean borders on excision• Low grade, low stage, MI <5• Breed – Boxers and PugsMultiple primary mast cell tumors do not

necessarily worsen prognosis• Dogs who tend to get one dermal MCT tend

to get more, simultaneously or sequentially• Warn owners to look for more when you

remove the first

Page 60: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

PrognosisAgNOR staining (MCT prognostic panel) • gives more information for grade II• Do chemo if high grade II• Amputate non-resectable low grade II• Cost is about $200 including shipping• Send MCT histopath to MSU or AMC, so you

can add the prognostic panel if grade II• Save center of tumor in formalin to send to

MSU /AMC for panel later if grade II• Can be difficult to get unstained paraffin

sections from the first lab (except TVMDL)

Page 61: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Client Handout• Mast Cell Tumors• Chemo agents discussed Sunday

Page 62: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Acknowledgements• Philip J. Bergman, DVM, MS, PhD, DACVIM

(Oncology)VIN Consultant, CMO BrightHeart Vet Centers

• Louis-Philippe de Lorimier, DVM, ACVIM (Oncology)VIN Consultant, U of Ill Urbana-ChampaignVisiting assistant professor, medical oncology

• Karri A. Meleo, DVM, ACVIM (Oncology), ACVRVIN Consultant, Vet Onc Serv, Edmonds, WA

Page 63: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Acknowledgements• Robert C. Rosenthal, DVM, BS, MS, PhD

VIN Consultant

• Kurt R. Verkest, BVSc, BVBiol, MACVSc (Small Animal)VIN Associate Editor, Univ Queensland, Australia

• Claudia Barton, DVM, ACVIM (Internal Medicine, Oncology)

TAMU CVM

Page 64: Practical Oncology Mast Cell Tumor Wendy Blount, DVM

Acknowledgements• Craig Clifford, DVM, MS, ACVIM (Oncology)

VIN Consultant